Found 6 matching trials
Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy PHASE3 This phase III trial compares survival in urothelial cancer patients who st...
Show More Status
Active Not Recruiting
Location
Anchorage Associates in Radiation Medicine
Learn More & Join Trial
Integrative Analysis of Tumor Microenvironment and Optimization of Immunotherapy Duration in NSCL Cancer Patients PHASE2 Non-comparative multicentric randomized study to assess long-term benefit o...
Show More Location
Centre Hospitalier de la Côte Basque
Learn More & Join Trial
Optimizing Ancillary Therapies With Immune Checkpoint Inhibitors for Solid Tumors (OAT ICI) PHASE2 This study evaluates whether optimization of ancillary therapies can improv...
Show More Location
University of Kentucky Markey Cancer Center
Learn More & Join Trial
Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase Inhibitors PHASE3 The purpose of this study is to demonstrate the non-inferiority of treatmen...
Show More Status
Active Not Recruiting
Location
CH de la Cote Basque - Service d'Oncologie
Learn More & Join Trial
Transcranial Magnetic Stimulation Study of Cortical Excitability as Marker of Antidepressant Response: EXCIPSY Study NA Depression is a common issue but there is no marker of response to an antid...
Show More Learn More & Join Trial
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors PHASE2 A prospective, open-label, multi-cohort, non-randomized, multicenter Phase ...
Show More Location
University of California, San Diego
Learn More & Join Trial